After Saunders’ return as CEO, Bausch + Lomb promotes three SVPs

Bausch + Lomb is making more executive change-ups, including the promotion of three of its senior VPs that will report directly to CEO Brent Saunders.

Brent Saunders

Earlier this year, Saunders returned to lead Bausch + Lomb and its roughly 12,000 employees after originally running the company from 2010 to 2013.

Bausch +Lomb said Thursday that Luc Bonnefoy, John Ferris and Yang Yang — the leaders of its surgical, consumer and vision care businesses, respectively — will join the executive management team and report directly to Saunders. It also said that Joseph Gordon, head of global consumer, surgical and vision care, is now a strategic advisor to Saunders.

John Ferris

“With these changes to the executive management team, our leaders will be closer to customers and patients,” he said in a statement, saying that would “set the stage for accelerated growth.”

Bausch + Lomb also said that Louis Yu, the eye care company’s chief quality officer, has notified the company that he intends to retire this summer, and the company will start an internal and external search for his replacement.

Yang Yang

Shares of $BLCO were up 1% Thursday morning.

This has been a busy several months for the ophthalmology company. After Saunders rejoined the company in February, he’s made several executive changes, including appointing Bob Bailey as chief legal officer and Andrew Stewart as the new president of its ophthalmic pharmaceuticals business.

Two weeks ago, Bausch + Lomb, alongside its partner Novaliq, got a treatment approved by the FDA for dry eye disease. The eye drops, perfluorohexyloctane ophthalmic solution or previously NOV03, will be branded as Miebo. The company said the drops are expected to be available in the second half of this year.

fda
shares
pharmaceuticals